A new method for reversible reentrant cannulation of the parotid duct in cattle by use of an injectable anesthetic regimen is described. Ruminal contents were removed before anesthesia instead of food deprivation. The parotid duct was dilated by means of a long hemostatic forceps: its jaws were encased in a piece of plastic tube, and the tip was extended by a piece of flexible wire. A polyethylene parotid catheter was inserted into the dilated duct and passed through the cheek. The saliva was re-directed back into the mouth via a silicone tube through another fistula in the cheek. The cannulations were maintained for 3 to 11 wk and two cows were recannulated three to five times in both parotid ducts without problems. No pathological changes of the mouth epithelium were found at slaughter. The rate of flow from the ducts during rest, ruminating, and eating were 5 to 20, 25 to 50, and 40 to 75 mL/min, respectively.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.2527/1996.7471716x | DOI Listing |
BMC Oral Health
January 2025
Department of Stomatology, Chinese PLA General Hospital, Beijing, China.
Background: Salivary duct carcinoma (SDC) is a highly aggressive salivary gland malignancy with poor prognosis. The aim was to investigate the prognostic factors and survival outcomes in a cohort of SDC patients.
Materials And Methods: This study retrospectively analyzed the clinicopathological data of 61 SDC patients treated at the First Medical Center of the PLA General Hospital between January 2010 and December 2020.
Cancer Rep (Hoboken)
January 2025
Department of Oncology and Hematology, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.
Backgroud: Salivary duct carcinoma (SDC) is a rare and aggressive malignancy with a generally dismal prognosis and no standard of care established, despite a known association with epidermal growth factor receptor 2 (HER2) and androgen receptor (AR) over-expression.
Case: We report the case of a 64-year-old female with extra- and intracranial metastases of SDC with evidence of AR and HER2 overexpression. After progression on first line chemotherapy, was administered neratinib, a pan-Erb2 receptor tyrosine kinase inhibitor.
Cureus
December 2024
Department of Basic and Clinical Oral Sciences, Umm Al-Qura University, Makkah, SAU.
Objectives: Head and neck malignancies (HNMs) encompass a variety of cancers that affect the oral and para-oral tissues, the most common of which are squamous cell carcinomas. Radiotherapy is commonly used to treat these cancers, often involving radiation exposure to the salivary glands. This study aims to investigate the early impacts of radiotherapy on the internal microstructure of the salivary gland cells and identify which gland exhibits the highest level of radiosensitivity.
View Article and Find Full Text PDFPLoS One
January 2025
Department of Morphological Sciences, Institute of Veterinary Medicine, Warsaw University of Life Sciences, Warsaw, Poland.
The study involved a gross anatomical description of the parotid gland, mandibular gland, monostomatic sublingual gland, polystomatic sublingual gland, and zygomatic gland in 12 adult Eurasian wolves (Canis lupus lupus) (wild free-ranging individuals and their zoo counterparts), including their morphometry and microscopic evaluation using hematoxylin & eosin, mucicarmine, azan trichrome, PAS, AB pH 1.0, AB pH 2.5; AB pH 2.
View Article and Find Full Text PDFMedicine (Baltimore)
January 2025
Department of Oral and Maxillofacial Surgery.
Rationale: When gland-preserving treatments are unsuccessful, sialoadenectomy is typically conducted for patients afflicted with submandibular gland diseases. The definitive treatment modality for these individuals is the removal of both the gland and the associated ducts. During surgery, the gland and the majority of the ducts can be excised utilizing the lateral transcervical approach, with residual ducts unlikely to develop pathology.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!